Aurinia Pharmaceuticals
AUPH
255 hedge funds and large institutions have $1.15B invested in Aurinia Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 88 increasing their positions, 82 reducing their positions, and 30 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
93% more call options, than puts
Call options by funds: $22M | Put options by funds: $11.4M
58% more capital invested
Capital invested by funds: $730M → $1.15B (+$423M)
50% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 30
5% more funds holding
Funds holding: 242 → 255 (+13)
4.87% more ownership
Funds ownership: 50.17% → 55.04% (+4.9%)
7% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 82
Top Buyers
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$11.9M |
| 2 |
Two Sigma Advisers
New York
|
+$11.7M |
| 3 |
Man Group
London,
United Kingdom
|
+$9.51M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$9.31M |
| 5 |
Millennium Management
New York
|
+$9.04M |
Top Sellers
AUPH Hedge Fund Activity: Q4 2025 in Review
255 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2025, worth a combined $1.15B — up 58% from $730M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new AUPH positions and 30 closed out — a net gain of 15 holders — while 88 added to existing stakes and 82 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $11.9M. The largest seller was Jump Financial, cutting an estimated $5.22M.
- 255 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2025, up from 242 in Q3 2025.
- Funds reported $1.15B of Aurinia Pharmaceuticals stock for Q4 2025, up 58% quarter-over-quarter.
- 45 funds opened new Aurinia Pharmaceuticals positions in Q4 2025 and 30 closed out, a net change of +15 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2025 was Nomura Holdings, an estimated $11.9M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2025 was Jump Financial, an estimated $5.22M sold.
Based on aggregated 13F filings for Q4 2025.